Coincidentally, Han W and other studies have shown that EGFR-TKIs, such as gefitinib and erlotinib, can activate autophagy of human lung cancer cells, and then the growth inhibitory effect of EGFR-TKIs on cancer cells is weakened (83). Here, EGFR is linked to lung carcinoma.